Study of prothrombotic molecules in type 1 diabetes mellitus children
DOI:
https://doi.org/10.47196/diab.v53i2.153Keywords:
diabetes, prothrombotic state, pai-1, von willebrand factor, scd40lAbstract
Introduction: hyperglycemia contributes to molecular changes that alter hemostasis.
Objectives: to determine molecules of a prothrombotic state in a child-juvenile population with type 1 diabetes (T1D), without clinical manifestation of vascular disease, and compare it with a control population.
Patients and methods: thirty-five patients with T1D (11.0±2.5 years and 3.7±2.0 years of disease duration), without vascular complications and 20 healthy controls were studied. Plasma fibrinogen (Pf), plasminogen activator inhibitor 1 (PAI-1), von Willebrand factor antigen vWF:Ag and soluble CD40 ligand (sCD40L) and coagulation global tests such as platelet count, prothrombin time (PT), activated partial thromboplastin time (APTT) were determined. The data obtained were analized by Statistics SPSS 20 software and were expressed as the mean±standard desviation. Pearson coefficient was used to investigate correlations between variables.
Results: diabetic patients presented significantly higher values of glycaemia, A1c, Fg (308± 66 vs 246±18 mg/dL, p=0.0001), PAI-1 (41.6±12 vs 11.7±1, 0 ng/mL, p=0.0001), vWF:Ag (284±55 vs 121±19%, p= 0.0001) and sCD40L (1608±109 vs 149±17 pg/mL,
p=0.0001). However, overall hemostasis tests showed no differences between both groups, PAI-1 and sCD40L correlated with glycemia, A1c, Fg and vWF:Ag.
Conclusions: high levels of Fg, PAI-1, vWF:Ag and sCD40L suggest the presence of a prothrombotic state in the infant population juvenil with DT1.
References
Vehik K, Dabelea D. The changing epidemiology of type 1 diabetes: why is it going through the roof? Diabetes Metab Res Rev 2011; 27(1):3-13.
Targher G, Chonchol M, Zoppini G, et al. Hemostatic disorders in type 1 diabetes mellitus. Semin Thromb Hemost 2011; 37(1):58-65.
Rodrigues TC, Snell-Bergeon JK, Maahs DM, et al. Higher fibrinogen levels predict progression of coronary artery calcification in adults with type 1 diabetes. Atherosclerosis 2010; 210(2):671-673.
Alessi MC, Poggi M, Juhan-Vague I. Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol 2007; 18(3):240-245.
Cesari M, Pahor M, Incalzi RA. Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther 2010; 28(5):72-91.
Gragnano F, Sperlongano S, Golia E, et al. The role of von Willebrand factor in vascular inflammation: from pathogenesis to targeted therapy. Mediators Inflamm 2017; 2017:5620314. Doi: 10.1155/2017/5620314.
Frankel DS, Meigs JB, Massaro JM, et al. Von Willebrand factor, type 2 diabetes mellitus, and risk of cardiovascular disease: the Framingham Offspring Study. Circulation 2008; 118(24): 2533-2539.
Madan R, Gupt B, Saluja S, et al. Coagulation profile in diabetes and its association with diabetic microvascular complications. J Assoc Physicians India 2010; 58:481-484.
Adly AA, Elbarbary NS, Ismail EA, et al. Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents with type 1 diabetes mellitus: relation to diabetic micro-vascular complications and carotid intima media thickness. J Diabetes Complications 2014; 28(3):340-347.
Antoniades C, Bakogiannis C, Tousoulis D, et al. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol 2009; 54(8):669-677.
Rizvi M, Pathak D, Freedman JE, et al. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med 2008; 14(12):530-538.
Carrizo T del R, Prado MM, Velarde MS, et al. Soluble E-selectin in children and adolescents with type 1 diabetes. Medicina 2008; 68(3):193-197.
Rabago-Rodríguez R, Gómez-Díaz RA, Tanus-Haj J, et al. Carotid intima-media thickness in pediatric type 1 diabetic patients. Diabetes Care 2007; 30(10):2599-2602.
Babar GS, Zidan H, Widlansky ME, et al. Impaired endothelial function in preadolescent children with type 1 diabetes. Diabetes Care 2011; 34(3):681-685.
Romano M, Pomilio M, Vigneri S, et al. Endothelial perturbation in children and adolescents with type 1 diabetes: association with markers of the inflammatory reaction. Diabetes Care 2001; 24(9):1674-1678.
Carmassi F, Morale M, Puccetti R, et al. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992; 67(6):643-654.
Blann AD, Lip GY. Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 diabetes mellitus. Diabet Med 1998; 15(8):634-642.
el Khawand C, Jamart J, Donckier J, et al. Hemostasis variables in type I diabetic patients without demonstrable vascular complications. Diabetes Care 1993; 16(8):1137-1145.
Sapkota B, Shrestha SK, Poudel S. Association of activated partial thromboplastin time and fibrinogen level in patients with type II diabetes mellitus. BMC Res Notes 2013; 6:485.
Targher G, Bertolini L, Zoppini G, et al. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med 2005; 22(8):999-1004.
Binay C, Bozkurt Turhan A, Simsek E, et al. Evaluation of coagulation profile in children with type 1 diabetes mellitus using rotational thromboelastometry. Indian J Hematol Blood Transfus 2017; 33(4):574-580.
Behl T, Velpandian T, Kotwani A. Role of altered coagulation-fibrinolytic system in the pathophysiology of diabetic retinopathy. Vascul Pharmacol 2017; 92:1-5.
Lemkes BA, Hermanides J, Devries JH, et al. Hyperglycemia: a prothrombotic factor? J Thromb Haemost 2010; 8(8):1663-1669.
Milne R, Brownstein S. Advanced glycation end products and diabetic retinopathy. Amino Acids 2013; 44(6): 1397-1407.
Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010; 106(8):1319-1331.
El-Asrar MA, Adly AA, Ismail EA. Soluble CD40L in children and adolescents with type 1 diabetes: relation to microvascular complications and glycemic control. Pediatr Diabetes 2012; 13(8):616-624.
Metwalley KA, Farghaly HS, El-Saied AR. Assessment of serum levels of soluble CD40L in Egyptian children and adolescents with type 1diabetes mellitus: relationship to microalbuminuria and glycemic control. Indian J Endocrinol Metab 2013; 17(6):1024-1029.
Targher G, Zoppini G. Soluble CD40L in young type 1 diabetic individuals without clinical microvascular and macrovascular complications. Diabetes Care 2004; 27(5): 1236-1237.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
